Navigation Links
Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology presents positive results of its pivotal phase III clinical trial positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC) at the XIV Afro-Asian Congress of ophthalmology (AACO) held from June 20 to 25 2007 in Marrakech (Morocco).

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability of Vekacia(R) was excellent.

The study was designed as a clinical phase II/III, multicenter, randomized parallel group, double masked, dose ranging, controlled study divided in two treatment periods: (I) a four-week prospective, randomized, multicenter, double-masked, three parallel-group, vehicle-controlled treatment period; and (II) a three-month prospective, multicenter, double-masked treatment period.

The primary objective of Vekacia(R) phase III study was to assess the efficacy of Vekacia(R) 0.05 % and Vekacia(R) 0.1%, administered four times daily, versus a vehicle after a four-week treatment period for patients with VKC. The secondary objectives were to compare the safety and ocular tolerance (objective and subjective) and the long-term safety after four months.

One hundred and eighteen patients (mean age: 8.8) with active bilateral VKC (acute or chronic) were enrolled in the study at over 21 sites in Europe and Mediterranean countries from May 2006 to October 2006. Most patients were suffering from perennial VKC (90 patients, 76.3%) and were presented
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:
(Date:11/20/2009)... Nov. 20 Reportlinker.com announce...n its catalogue. ,, Medical Adhesives and Seal...rtlinker.com/p0164242/Medical-Adhesives-and-Sealan...&utm_medium=pr&utm_campaign=prnewswire ,...gaining preeminence in medical devices and equipme...
(Date:11/20/2009)..., N.J., Nov. 20 BD (Bect...nounced the completion of its acquisition of Handy...at develops and manufactures molecular diagnostic ..., BD and HandyLab announced an exclusive agreement...ays on the HandyLab Jaguar(TM) platform, the first...
(Date:11/19/2009)...Nov. 19 In response to an ever-inc... illegal medicines, Operation Pangea II, involving... World Health Organization,s International Medical...o highlight the dangers of buying medicines online...n a series of arrests and the seizure of thousands...
Breaking Medicine Technology:Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 1Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 2Announcing Sustainability in Packaging 2010 3A Strategies to make sustainability sustainable 13946 3First Cape Cod Macular Degeneration Symposium To Be Held on September 17 56628 1First Cape Cod Macular Degeneration Symposium To Be Held on September 17 56628 2First Cape Cod Macular Degeneration Symposium To Be Held on September 17 56628 3Michigan Pre Seed Capital Fund Awards Three Micro Loans 13945 1Michigan Pre Seed Capital Fund Awards Three Micro Loans 13945 2
...Nova BioSciences, Inc.,("CeloNova"), leading and a...sion and development of innovative medical devices... 8 country European study of uterine fibroid,embol...res. The study,results were reported at the 20th A...apy., (Photo: http://www.newscom.com/cgi-bin/prn...
...on for HUMIRA Provides Patients with Visible, Cle...Autoimmune Disease, ABBOTT PARK, Ill., Jan. 18 A...d U.S. Food and Drug Administration (FDA),approval...or adult patients,with moderate to severe chronic ...zed by skin lesions that are sometimes painful and...
Other Medicine Technology:CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 3Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 4Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 5Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 6Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 7
(Date:11/20/2009)...od pressure readings in children with chronic kidn... during doctor,s office visits increasing a child...esearch from Johns Hopkins Children,s Center and o...s online in the Journal of American Society of Nep... measurements obtained during regular doctor visit...
(Date:11/20/2009)...nks it,s as short as 34 weeks, potentially adding ..., FRIDAY, Nov. 20 (HealthDay News) -- Recent repor...ues to climb in the United States. Now, a new stu...d about what constitutes a full-term birth in the ... surveyed in the study considered a baby born at 3...
(Date:11/20/2009)...ctivity remains high and is expected to continue, ...y News) -- Some areas of the United States are see... health official said Friday, and while the diseas...m the 46 states reported last week. , "We are b...y around the country, but there is still a lot of ...
(Date:11/20/2009)... SPRINGFIELD, Mo., Nov. 20 Missour...al Missouri regions will now have the option to ch...ched Tuesday between Missouri Consolidated Health ...e Southwest and South Central Missouri regions inc... Christian, Dade, Dallas, Douglas, Greene, Hickory...
(Date:11/20/2009)... BATON ROUGE, La., Nov. 20 /PRNewswire-USNewswir...(LAHP) today warned that Louisianians could experi...its if proposals being considered by Congress shou... executive officer for LAHP, "Louisiana health pla... since the beginning of the national debate. Our ...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...7 Merck & Co., Inc.,today said that it has not ye...k State and New York City seeking Medicaid reimbur...t the suit as it has defended against the,Medicaid...ug Administration (FDA) approval, and consistently...
...or Living,Inc. (NYSE: BKD ) announced today that ...sh dividend on its common stock of $0.50 per share....50 per share dividend is payable,on October 12, 2...ving facilities throughout the United States. The ...
...Biosciences,Inc. (LSE: AKR) which develops, manufa...g and testing products, is pleased to announce tha...Army for the purchase of its,BreathScan alcohol sa...gnificant,orders from several departments of the U...
... Focus on Cardiovascular Disease, Prevention and ...e Care Improvements, ...Charlie,Rose Science Series" on PBS will focus on ...l Laureate and President of,Rockefeller University...
...hat patients with cancer in the head and neck regi...kills compared with individuals without the diseas... Archives of Otolaryngology-Head & Neck Surgery, o...ork together. These functions can be compromised t...
...rday, October 20,Event to be held in honor of Octo...PLAINS, Mo., Sept. 17 GAMMILL QUILTING SYSTEMS, a...ngarm quilting systems, in,cooperation with it,s n...tional Breast Cancer Awareness Month; and in,suppo...
Other Medicine News:Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 2Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 3Health News:Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts 2Health News:Charlie Rose Science Series Explores Heart Disease 2Health News:Charlie Rose Science Series Explores Heart Disease 3Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:'Think Pink with Gammill(R)' 2
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: